SS Innovations International Inc. (NASDAQ: SSII) has reported record second-quarter revenue of $13.9 million, a 39.4% increase year over year, signaling continued momentum for its SSi Mantra surgical robotic platform. The company's first-half revenue reached $25.0 million, up 65.6% from the same period in 2025, driven by strong demand for its robotic surgery systems.
The company installed 30 SSi Mantra systems during the quarter, a 30.4% rise, bringing the total installed base to 224 systems across 12 countries. Cumulative surgeries performed with the platform reached 12,272, underscoring its growing clinical adoption. These figures highlight the company's progress in expanding its global footprint and solidifying its position in the surgical robotics market.
Gross profit for the second quarter increased 20.0% to $7.1 million, though gross margin declined to 50.9% from 59.1% in the year-earlier quarter. For the first half, gross profit rose 77.5% to $12.4 million, with gross margin improving, according to the company's financial report (https://nnw.fm/zxrT1). The margin fluctuation may reflect increased investments in production and scaling efforts as the company prepares for regulatory milestones.
Key catalysts on the horizon include U.S. Food and Drug Administration (FDA) clearance, targeted for the first quarter of 2027, and European CE marking, expected by the end of 2026. These approvals would open significant markets and could substantially expand the addressable customer base for SSi Mantra. The company's telesurgery achievements are also extending the clinical profile of the platform, though system installations remain the primary commercial growth driver.
The strong revenue growth and expanding installed base suggest that SS Innovations is gaining traction in the competitive surgical robotics sector, which has been dominated by a few major players. The company's focus on innovative technology and global expansion positions it to capitalize on the increasing demand for minimally invasive surgical options.
Investors and industry observers will be watching closely as SS Innovations progresses toward its regulatory goals. Successful FDA and CE approvals could not only boost the company's revenue trajectory but also enhance its credibility and competitiveness in the global market. The company's performance in the coming quarters will be crucial in determining whether it can sustain this growth momentum and achieve its strategic objectives.
For more information on SS Innovations, visit the company's newsroom at https://nnw.fm/SSII.
